Abstract
Alzheimer’s disease (AD) is the most common form of late-onset neurodegenerative disease. Previous genome-wide association studies have identified numerous common genetic variants associated with AD. The contribution of rare variants to AD remains to be uncovered. AD-by-proxy, based on parental AD status, showed superior statistical power boost in recent AD studies. Using the UK Biobank (UKB) 368,865 whole-exome sequences of white British ancestry and AD-by-proxy (57,976 proxy AD cases and 310,889 non-AD proxy controls), we conducted the largest exome-wide association study of proxy AD to date. We identified 38 novel genes harboring rare variants for AD, such as ANKRD36 (P = 6.02 × 10−31), MMP13 (P = 1.08 × 10−6), TUBA4A (P = 7.15 × 10−12), and ZNF296 (P = 4.19 × 10−14), demonstrating the power boost of aggregating rare variants and utilizing AD-by-proxy in gene discovery. We further replicated these genes in the FinnGen dataset. Notably, MMP13 is a current drug target for AD and TUBA4A is a drug target for cognitive impairment in clinical trials. These results expand our knowledge of the genetic architecture of AD, especially the role of rare variants, and potential drug targets for AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants from the National Institute on Aging, National Institutes of Health (NIH; Bethesda, MD, USA): RF1AG060472
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank gave ethical approval for this work (project 23424)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
